Back to Search
Start Over
Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
- Source :
-
Rheumatology International . Mar2016, Vol. 36 Issue 3, p349-357. 9p. 2 Charts, 2 Graphs. - Publication Year :
- 2016
-
Abstract
- Predicting the responses of patients with rheumatoid arthritis (RA) to tocilizumab is difficult, because inflammatory markers such as C-reactive protein rapidly normalize regardless of clinical efficacy. We aimed to identify factors that could predict response to tocilizumab. Sixty-five patients completed 52 weeks of tocilizumab therapy. Serum fibrinogen, D-dimer and interleukin (IL)-1β levels were measured at baseline and after 4 weeks of therapy. Clinical responses to tocilizumab were assessed using disease activity score 28-erythrocyte sedimentation rate and the clinical disease activity index at baseline and after 52 weeks of therapy (UMIN Clinical Trials Registry No. UMIN000002246). Mean age was 60.5 years (range 22-85 years). Mean disease duration was 11.2 years (range 0-45 years). All patients had moderate-to-severe disease activity and were resistant to disease-modifying anti-rheumatic drugs and/or other biologics. Baseline IL-1β levels were significantly lower in responders than in non-responders ( p = 0.045), but multiple logistic regression analysis found no significant difference (adjusted odds ratio 2.74; 95 % confidence interval 0.84-8.95; p = 0.096). Low D-dimer and IL-1β levels at 4 weeks predicted greater decrease in disease activity after 52 weeks of treatment ( p = 0.005 and p < 0.001, respectively). Effects of tocilizumab at 52 weeks could be predicted from D-dimer and IL-1β levels after 4 weeks of tocilizumab treatment. These markers might be more useful than current inflammatory markers for early-stage prediction of response to tocilizumab in RA. [ABSTRACT FROM AUTHOR]
- Subjects :
- *RHEUMATOID arthritis treatment
*INTERLEUKIN-1
*TOCILIZUMAB
*BIOMARKERS
*FIBRINOGEN
Subjects
Details
- Language :
- English
- ISSN :
- 01728172
- Volume :
- 36
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Rheumatology International
- Publication Type :
- Academic Journal
- Accession number :
- 113084167
- Full Text :
- https://doi.org/10.1007/s00296-015-3379-x